View in EDS

NM101 Phase III study of NE3107 in Alzheimer's disease: rationale, design and therapeutic modulation of neuroinflammation and insulin resistance.

Saved in:
Bibliographic Details
Title: NM101 Phase III study of NE3107 in Alzheimer's disease: rationale, design and therapeutic modulation of neuroinflammation and insulin resistance.
Authors: Reading CL; BioVie, Inc., San Diego, CA 92122, USA., Ahlem CN; BioVie, Inc., San Diego, CA 92122, USA., Murphy MF; Worldwide Clinical Trials, Morrisville, NC 27560, USA.
Source: Neurodegenerative disease management [Neurodegener Dis Manag] 2021 Aug; Vol. 11 (4), pp. 289-298. Date of Electronic Publication: 2021 Jul 12.
Publication Type: Clinical Trial Protocol; Journal Article
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101517977 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1758-2032 (Electronic) Linking ISSN: 17582024 NLM ISO Abbreviation: Neurodegener Dis Manag Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34251287
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: NM101 Phase III study of NE3107 in Alzheimer's disease: rationale, design and therapeutic modulation of neuroinflammation and insulin resistance.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Reading+CL%22">Reading CL</searchLink>; BioVie, Inc., San Diego, CA 92122, USA.<br /><searchLink fieldCode="AU" term="%22Ahlem+CN%22">Ahlem CN</searchLink>; BioVie, Inc., San Diego, CA 92122, USA.<br /><searchLink fieldCode="AU" term="%22Murphy+MF%22">Murphy MF</searchLink>; Worldwide Clinical Trials, Morrisville, NC 27560, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101517977%22">Neurodegenerative disease management</searchLink> [Neurodegener Dis Manag] 2021 Aug; Vol. 11 (4), pp. 289-298. <i>Date of Electronic Publication: </i>2021 Jul 12.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial Protocol; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101517977 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1758-2032 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2217582024%22">17582024 </searchLink><i>NLM ISO Abbreviation: </i>Neurodegener Dis Manag <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34251287
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.2217/nmt-2021-0022
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 289
    Titles:
      – TitleFull: NM101 Phase III study of NE3107 in Alzheimer's disease: rationale, design and therapeutic modulation of neuroinflammation and insulin resistance.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Reading CL
      – PersonEntity:
          Name:
            NameFull: Ahlem CN
      – PersonEntity:
          Name:
            NameFull: Murphy MF
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2021 Aug
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 1758-2032
          Numbering:
            – Type: volume
              Value: 11
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Neurodegenerative disease management
              Type: main
ResultId 1